Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polysaccharide superparamagnetic iron oxide for CMR in diabetic CKD
NCT06051565Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ferumoxytol in atherosclerosis, chronic venous disease (CVD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2021; status: completed.
02
Drugs
ferumoxytol
03
Conditions
atherosclerosischronic venous disease (CVD)
Beyond the preview
Go deeper on NCT06051565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051565.